
1. indian j med res. 2009 sep;130(3):261-5.

the clinical utility hpv dna testing cervical cancer screening strategies.

bhatla n(1), moda n.

author information: 
(1)department obstetrics & gynaecology, india institute medical
sciences, new delhi, india. nbhatla@aiims.ac.in

cervical cancer continues commonest cause death among women in
developing countries, largely due failure inability sustain
effective cytology-based screening programs. burden may come down
following implementation human papillomavirus (hpv) vaccine, screening
will still required. hpv dna testing promising new technology for
cervical cancer prevention reproducible cervical cancer
screening tests. presently, two assays widely used detection 
genital types polymerase chain reaction (pcr) hybrid capture 2 assays
(hc2). rapid, affordable tests expected available soon. hpv dna testing
can used variety clinical scenarios include primary screening 
women older 30 yr; adjunctive test cytology; triage women
with equivocal cytologic report, e.g., asc-us; follow-up post-treatment
for cervical intraepithelial neoplasia (cin). hpv dna testing also be
performed self-collected samples, allows screening remote areas and
also women refuse gynecologic examination.


pmid: 19901435  [indexed medline]

